The Calmer Co. International Limited announces a leadership change with James S. Tonkin appointed Chairman as the company accelerates its U.S. market growth in natural kava products.
Rhythm Biosciences has successfully validated its ColoSTAT® colorectal cancer test, secured its first strategic partnership for Genetype, and secured $1 million in non-dilutive funding, setting the stage for a transformative FY26.
NOVONIX announces the departure of CEO Dr. Chris Burns, with CFO Robert Long stepping in as interim CEO amid plans to scale production at its Riverside facility.
